Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nebivolol/rosuvastatin - Elyson Pharmaceutical

Drug Profile

Nebivolol/rosuvastatin - Elyson Pharmaceutical

Alternative Names: EL-1401; Rosuvastatin/nebivolol - Elyson Pharmaceutical

Latest Information Update: 28 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Elyson Pharm
  • Class Antihyperlipidaemics; Antihypertensives; Benzopyrans; Ethanolamines; Fluorobenzenes; Heart failure therapies; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Beta 1 adrenergic receptor antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Hyperlipidaemia; Hypertension

Most Recent Events

  • 14 Jan 2020 Elyson Pharmaceutical completes a phase III trial in Hyperlipidaemia and Hypertension in South Korea (PO) (KCT0002148)
  • 31 Mar 2017 Elyson Pharmaceutical completes a phase I trial in Healthy volunteers in South Korea (PO) (KCT0002283)
  • 07 Mar 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top